Course:
CME Credits: 0.00
Released: 2025-04-04
Cytomegalovirus (CMV) is a serious pathogen that leads to considerable illness and death in hematopoietic cell transplant (HCT) patients. The landscape for CMV prevention and treatment in this vulnerable population continues to evolve, with newer antiviral therapies offering efficacy and minimal side effects. Optimal CMV management should include an individualized approach based on current guidelines, transplant conditioning regimens, treatment toxicities, and potential CMV drug resistance. Join our distinguished panel as they review state-of-the-art therapeutic considerations for managing CMV in HCT patients, including insights on a challenging clinical case from their practice.
Upon completion of this activity, participants should be better able to:
View Full Course